Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 12, 2025 • 3:21 PM ET

Date/Time Source News Release
06/03/2025 07:00 AM EDT GlobeNewswire BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
05/28/2025 07:00 AM EDT GlobeNewswire BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
05/12/2025 04:30 PM EDT GlobeNewswire BeyondSpring Reports First?Quarter 2025 Financial Results and Provides Corporate Update
03/27/2025 07:05 AM EDT GlobeNewswire BeyondSpring Files 2024 Annual Report on Form 10-K
03/27/2025 07:00 AM EDT GlobeNewswire BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones
01/28/2025 07:00 AM EST GlobeNewswire SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
01/28/2025 07:00 AM EST GlobeNewswire BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
11/11/2024 08:00 AM EST GlobeNewswire BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
09/16/2024 07:00 AM EDT GlobeNewswire BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024
09/16/2024 07:00 AM EDT GlobeNewswire BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
Page

Additional News

As of June 12, 2025 • 3:21 PM ET

Date/Time Source News Release
06/12/2025 10:16 AM EDT Baystreet Big Cuts to U.S. Cancer Research May Create Historic Opening for Biotech Investors
05/12/2025 05:25 PM EDT SeekingAlpha BeyondSpring GAAP EPS of -$0.08
03/27/2025 07:23 AM EDT SeekingAlpha BeyondSpring GAAP EPS of -$0.21
01/28/2025 07:22 AM EST SeekingAlpha BeyondSpring sells stake in preferred shares of SEED Therapeutics for ~$35.4M
09/16/2024 05:14 PM EDT SeekingAlpha BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC
07/29/2024 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Monday, July 29th, 2024
07/29/2024 05:37 AM EDT US Earnings Reports Expected earnings - BeyondSpring Inc.
06/12/2024 05:32 PM EDT SeekingAlpha BeyondSpring files to offer up to 10M ordinary shares
05/23/2024 04:30 PM EDT QM US Market Movers News US Companies Moving the Markets, Evening edition
Thu, May 23, 2024 as of 4:00 pm ET
05/09/2024 05:34 AM EDT US Earnings Reports Expected earnings - BeyondSpring Inc.
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.